Association of good oncological response to therapy with the development of rheumatic immune ‐related adverse events following PD‐1 inhibitor therapy

ConclusionRheumatic irAEs are relatively common with PD ‐1 inhibitor therapy, and appear to be associated with a good oncological response to therapy. Many rheumatic irAEs were not referred to rheumatological services. Prospective systematic investigation would be of benefit to explore these characteristics.

Source: APLAR Journal of Rheumatology - November 22, 2018 Category: Rheumatology Authors: David F. L. Liew, Jessica L. Y. Leung, Bonnia Liu, Jonathan Cebon, Albert G. Frauman, Russell R. C. Buchanan Tags: ORIGINAL ARTICLE Source Type: research